• Publikationen

    2020

    Foray C, Barca C, Backhaus P, Schelhaas S, Winkeler A, Viel T, Schafers M, Grauer O, Jacobs AH, Zinnhardt B. Multimodal Molecular Imaging of the Tumour Microenvironment. Adv Exp Med Biol 2020;1225: 71-87. Abstract

    2019

    Kailayangiri S, Altvater B, Lesch S, Balbach S, Gottlich C, Kuhnemundt J, Mikesch J-H, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Muller I, Walles H, Hartmann W, Rossig C. EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. Mol Ther 2019;27: 933-946. Abstract

    2018

    Schelhaas S, Heinzmann K, Honess DJ, Smith D-M, Keen H, Heskamp S, Witney TH, Besret L, Doblas S, Griffiths JR, Aboagye EO, Jacobs AH. 3'-Deoxy-3'-[(18)F]Fluorothymidine Uptake Is Related to Thymidine Phosphorylase Expression in Various Experimental Tumor Models. Mol Imaging Biol 2018;20: 194-199. Abstract
    Schelhaas S, Wachsmuth L, Hermann S, Rieder N, Heller A, Heinzmann K, Honess DJ, Smith D-M, Fricke IB, Just N, Doblas S, Sinkus R, Doring C, Schafers KP, Griffiths JR, Faber C, Schneider R, Aboagye EO, Jacobs AH. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-(18)F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model. J Nucl Med 2018;59: 1063-1069. Abstract

    2017

    Fricke IB, Schelhaas S, Zinnhardt B, Viel T, Hermann S, Couillard-Despres S, Jacobs AH. In vivo bioluminescence imaging of neurogenesis - the role of the blood brain barrier in an experimental model of Parkinson's disease. Eur J Neurosci 2017;45: 975-986. Abstract
    Heinzmann K, Honess DJ, Lewis DY, Smith D-M, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM. Correction to: The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models. EJNMMI Res 2017;7: 99. Abstract
    Schelhaas S, Heinzmann K, Bollineni VR, Kramer GM, Liu Y, Waterton JC, Aboagye EO, Shields AF, Soloviev D, Jacobs AH. Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review. Theranostics 2017;7: 40-50. Abstract
    Waerzeggers Y Zinnhardt B Winkeler A Monfared P Schelhaas S Viel T Jacobs AH. Imaging in Neurooncology. In: Kiessling F., Pichler B. Small Animal Imaging 2017;Springer, Cham: 689-725. Abstract
    Zinnhardt B, Pigeon H, Theze B, Viel T, Wachsmuth L, Fricke IB, Schelhaas S, Honold L, Schwegmann K, Wagner S, Faust A, Faber C, Kuhlmann MT, Hermann S, Schafers M, Winkeler A, Jacobs AH. Combined PET Imaging of the Inflammatory Tumor Microenvironment Identifies Margins of Unique Radiotracer Uptake. Cancer Res 2017;77: 1831-1841. Abstract

    2016

    Heinzmann K, Honess DJ, Lewis DY, Smith D-M, Cawthorne C, Keen H, Heskamp S, Schelhaas S, Witney TH, Soloviev D, Williams KJ, Jacobs AH, Aboagye EO, Griffiths JR, Brindle KM. The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models. EJNMMI Res 2016;6: 63. Abstract
    Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. OncoImmunology 2016: e1250050. Abstract
    Schelhaas S, Held A, Baumer N, Viel T, Hermann S, Muller-Tidow C, Jacobs AH. Preclinical Evidence That 3'-Deoxy-3'-[18F]Fluorothymidine PET Can Visualize Recovery of Hematopoiesis after Gemcitabine Chemotherapy. Cancer Res 2016;76: 7089-7095. Abstract
    Schelhaas S, Held A, Wachsmuth L, Hermann S, Honess DJ, Heinzmann K, Smith D-M, Griffiths JR, Faber C, Jacobs AH. Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer. Cancer Res 2016;76: 7096-7105. Abstract

    2015

    Baumer S, Baumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Muller-Tidow C. Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer. Clin Cancer Res 2015;21: 1383-1394. Abstract
    Bulk E, Ay A-S, Hammadi M, Ouadid-Ahidouch H, Schelhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Marra A, Hillejan L, Jacobs AH, Klein H-U, Dugas M, Berdel WE, Muller-Tidow C, Schwab A. Epigenetic dysregulation of KCa 31 channels induces poor prognosis in lung cancer. Int J Cancer 2015;137: 1306-1317. Abstract
    Fahrlander E, Schelhaas S, Jacobs AH, Langer K. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. Nanotechnology 2015;26: 145103. Abstract

    2014

    Schelhaas S, Wachsmuth L, Viel T, Honess DJ, Heinzmann K, Smith D-M, Hermann S, Wagner S, Kuhlmann MT, Muller-Tidow C, Kopka K, Schober O, Schafers M, Schneider R, Aboagye EO, Griffiths J, Faber C, Jacobs AH. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-18F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. J Nucl Med 2014;55: 983-988. Abstract

    2013

    Steingräber AK, Schelhaas S, Faust A, Jacobs AH, Schäfers M, Goerge T. Molecular imaging reveals time course of MMP activity in acute cutaneous vasculitis in vivo. Exp Dermatol 2013;22: 730-735. Abstract
    Viel T, Monfared P, Schelhaas S, Fricke IB, Kuhlmann MT, Fraefel C, Jacobs AH. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology. Mol Ther 2013;21: 570-579. Abstract
    Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, Faber C, Kopka K, Schafers M, Jacobs AH. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. PLoS One 2013;8: e67911. Abstract
    Waerzeggers Y, Viel T, Schäfers S, Wagner S, Faust A, Riemann B, Kopka K, Schober O, Schäfers K, Jacobs AH. Positron Emission Tomography (PET)-based Molecular Imaging. Part 5 - Imaging Technologies in Animal Tumor Models: Measuring Brain Tumor Growth and Metabolism 2013;Neuromethods; 77: 301-327.

    2011

    Schmidt LH, Spieker T, Koschmieder S, Schäfers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, Müller-Tidow C. The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth. J Thorac Oncol 2011;6: 1984-1992. Abstract